FFAR4 and polycystic ovary syndrome: At weeks two and three of treatment, the PCOS-IR+GPR120 group and the PCOS-IR+LrB (40 mg/kg) group presented significant reductions in body weight (Figure 2C,D); the PCOS-IR+LrB (20 mg/kg) group also showed significant reductions in body weight (Figure 2C,D).